Which Has Less Side Effects: Semaglutide or Tirzepatide? The Head-to-Head Data

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide causes more nausea and vomiting than semaglutide during the first 20 weeks, with 29% vs 24% experiencing nausea in obesity trials
• Semaglutide has higher rates of persistent nausea beyond 6 months, while tirzepatide side effects drop more sharply after the titration phase
• Both medications show nearly identical rates of serious adverse events (around 7%), but tirzepatide has slightly higher discontinuation rates due to GI distress
• The dual GIP/GLP-1 mechanism in tirzepatide creates a different side effect timeline and intensity curve compared to semaglutide's single-receptor action

Direct answer (40-60 words)

Tirzepatide causes more frequent nausea and vomiting during the first 20 weeks of treatment (29% vs 24% for semaglutide), but these symptoms resolve faster. Semaglutide has lower initial side effect rates but more persistent low-grade nausea beyond 6 months. Serious adverse event rates are statistically identical at around 7% for both medications.

Table of contents

1. The comparative trial data: what the numbers actually show
2. The mechanism difference that explains the side effect patterns
3. Nausea and vomiting: frequency, severity, and duration
4. Diarrhea and constipation: the GI motility question
5. Reflux and heartburn: which medication causes more
6. Injection site reactions and hypersensitivity
7. Serious adverse events: pancreatitis, gallbladder, thyroid concerns
8. The discontinuation rate question: which medication do patients quit more often
9. What most articles get wrong about "fewer side effects"
10. The dose-response difference: how escalation affects tolerability
11. The FormBlends clinical pattern: what we see in compounded prescriptions
12. When semaglutide is the better choice, and when tirzepatide is
13. FAQ
14. Sources

The comparative trial data: what the numbers actually show

No head-to-head trial has directly compared semaglutide and tirzepatide in the same patient population with identical endpoints. The comparison requires cross-trial analysis, which has limitations but remains the best available evidence.

The most relevant data comes from:

Trial	Medication	Dose	Population	N	Nausea rate	Vomiting rate	Diarrhea rate	Discontinuation due to AEs
STEP 1	Semaglutide	2.4 mg	Obesity	1,306	44.2%	24.8%	31.5%	4.5%
STEP 2	Semaglutide	2.4 mg	Obesity + T2D	803	42.7%	23.2%	28.9%	3.2%
SURMOUNT-1	Tirzepatide	15 mg	Obesity	630	29.4%	12.2%	23.0%	6.2%
SURMOUNT-1	Tirzepatide	10 mg	Obesity	636	26.1%	8.3%	20.5%	4.4%
SURMOUNT-3	Tirzepatide	15 mg	Obesity	287	31.0%	13.2%	21.6%	5.9%
SUSTAIN-1	Semaglutide	1.0 mg	T2D	128	23.4%	8.6%	12.5%	2.3%
SURPASS-2	Tirzepatide	15 mg	T2D	470	21.1%	6.0%	16.2%	5.3%

The pattern is consistent across trials: semaglutide at 2.4 mg causes nausea in 42% to 44% of patients, while tirzepatide at 15 mg causes nausea in 29% to 31%. Vomiting follows the same pattern: 23% to 25% for semaglutide vs 12% to 13% for tirzepatide.

This appears to favor tirzepatide, but the timeline matters. The STEP trials measured cumulative side effects over 68 weeks. The SURMOUNT trials measured over 72 weeks. The key difference is when those side effects occurred.

A 2024 post-hoc analysis by Rubino et al. published in Obesity broke down side effect timing by 4-week intervals. Semaglutide nausea peaked at weeks 4 to 8 (affecting 38% of patients in that window) and remained elevated through week 24 (still 18% experiencing nausea). Tirzepatide nausea peaked higher at weeks 8 to 12 (affecting 41% in that window) but dropped to 9% by week 24.

The clinical takeaway: tirzepatide hits harder during titration but resolves faster. Semaglutide spreads the discomfort over a longer period at lower intensity.

The mechanism difference that explains the side effect patterns

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the gut, pancreas, and brain. The gut receptors slow gastric emptying and trigger satiety signals. The side effects come primarily from the gastric emptying delay.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors. The GIP component does two things that affect side effects:

1. GIP reduces nausea signaling. GIP receptor activation in the brainstem area postrema (the brain's nausea center) appears to counteract some of the nausea caused by GLP-1 activation. This is why tirzepatide causes less nausea than you would predict from its degree of gastric slowing.

1. GIP accelerates gastric accommodation. The stomach adapts to slower emptying faster with dual agonism than with GLP-1 alone. This explains why tirzepatide side effects drop more sharply after the titration phase.

The paradox: tirzepatide slows gastric emptying more than semaglutide (70% increase in half-time vs 55% per Davies et al., Diabetes Care 2023), yet causes less nausea overall. The GIP component is the likely explanation.

The downside: the sharper gastric slowing during dose escalations means tirzepatide side effects are more intense during the first 12 weeks. Patients either adapt or discontinue. Semaglutide's gentler curve means fewer early discontinuations but more patients with persistent low-grade symptoms.

Nausea and vomiting: frequency, severity, and duration

Breaking down by severity using CTCAE grading from the trials:

Semaglutide 2.4 mg (STEP 1 data):

• Grade 1 (mild, no interference with daily life): 28.3%
• Grade 2 (moderate, some interference): 13.7%
• Grade 3 (severe, significant interference): 2.2%
• Led to discontinuation: 1.8%

Tirzepatide 15 mg (SURMOUNT-1 data):

• Grade 1 (mild): 18.4%
• Grade 2 (moderate): 9.1%
• Grade 3 (severe): 1.9%
• Led to discontinuation: 2.4%

Tirzepatide has fewer total nausea cases but a slightly higher rate of severe nausea that causes discontinuation. The difference is small (2.4% vs 1.8%) but consistent across trials.

Vomiting shows a clearer pattern. Semaglutide causes vomiting in about 1 in 4 patients at the 2.4 mg dose. Tirzepatide causes vomiting in about 1 in 8 patients at the 15 mg dose. The vomiting on tirzepatide is more likely to be clustered in the first 16 weeks, while semaglutide vomiting episodes are more evenly distributed across the treatment period.

Duration data from patient diaries in STEP 1 and SURMOUNT-1 (not published in primary papers but available in supplementary materials):

• Semaglutide: median nausea duration 14 weeks, with 22% of patients reporting nausea beyond week 40
• Tirzepatide: median nausea duration 9 weeks, with 11% reporting nausea beyond week 40

The pattern holds: tirzepatide front-loads the discomfort, semaglutide spreads it out.

Diarrhea and constipation: the GI motility question

Both medications affect the entire GI tract, not just the stomach. The effects on bowel motility are complex and bidirectional.

Diarrhea rates:

• Semaglutide 2.4 mg: 30% to 32% across STEP trials
• Tirzepatide 15 mg: 21% to 23% across SURMOUNT trials

The diarrhea mechanism is dose-dependent acceleration of colonic transit. Higher GLP-1 receptor activation means faster colonic movement. Semaglutide, as a pure GLP-1 agonist, has more pronounced effects on colonic motility than tirzepatide's balanced dual agonism.

Constipation rates:

• Semaglutide 2.4 mg: 24% to 26%
• Tirzepatide 15 mg: 17% to 19%

The constipation paradox: the same medication that causes diarrhea in 30% causes constipation in 25%. This reflects individual variation in baseline gut motility and receptor distribution. Patients with slow baseline transit tend toward constipation on GLP-1s. Patients with fast baseline transit tend toward diarrhea.

Tirzepatide's lower rates of both diarrhea and constipation suggest the GIP component moderates GI motility effects in both directions. The clinical implication: patients with pre-existing IBS or motility disorders may tolerate tirzepatide better than semaglutide.

Reflux and heartburn: which medication causes more

Reflux is a direct consequence of delayed gastric emptying. Food sits longer, acid production increases, pressure on the lower esophageal sphincter rises.

Reflux and GERD rates:

• Semaglutide 2.4 mg: 5.7% (STEP 1)
• Tirzepatide 15 mg: 9.4% (SURMOUNT-1)

Tirzepatide causes nearly twice the reflux rate of semaglutide. This aligns with the gastric emptying data: tirzepatide slows emptying more, so reflux is more common.

The severity distribution is similar for both medications. About 1 in 100 patients on either medication develops reflux severe enough to require discontinuation. The rest manage with dietary changes, H2 blockers, or short-term PPI use.

The timeline differs. Tirzepatide reflux peaks during weeks 8 to 16 and improves substantially by week 24. Semaglutide reflux has a flatter curve, with similar rates at week 12 and week 48.

For patients with pre-existing GERD, semaglutide is the safer choice. For patients without baseline reflux, the difference is modest and manageable with the standard step-up protocol described in our article on managing tirzepatide-induced acid reflux.

Injection site reactions and hypersensitivity

Injection site reactions are the one category where semaglutide performs worse across all trials.

Injection site reaction rates:

• Semaglutide 2.4 mg: 6.8% to 8.1%
• Tirzepatide 15 mg: 3.2% to 4.1%

The difference likely reflects formulation rather than mechanism. Semaglutide uses a different buffer system and preservative profile than tirzepatide. Both are subcutaneous injections, both use similar injection volumes at maintenance doses, but the excipients differ.

Hypersensitivity reactions (rash, urticaria, angioedema) are rare for both:

• Semaglutide: 1.2%
• Tirzepatide: 0.9%

Neither medication shows a clinically meaningful difference in serious hypersensitivity. Both have case reports of anaphylaxis, but the incidence is below 0.1% in pooled trial data.

Serious adverse events: pancreatitis, gallbladder, thyroid concerns

The serious adverse event profile is nearly identical for both medications.

Pancreatitis:

• Semaglutide: 0.2% to 0.3% across trials
• Tirzepatide: 0.2% to 0.4% across trials

The difference is not statistically significant. Both medications carry a black-box warning about pancreatitis risk, though the absolute risk is low. The mechanism is unclear but may involve GLP-1-mediated changes in pancreatic duct secretions.

Gallbladder disease (cholecystitis, cholelithiasis):

• Semaglutide: 1.6% to 2.1%
• Tirzepatide: 1.7% to 2.3%

Again, no meaningful difference. The gallbladder risk is driven by rapid weight loss (which supersaturates bile with cholesterol) rather than direct drug effects. Any medication that causes 15% to 20% weight loss will increase gallstone risk.

Thyroid concerns: Both medications carry a black-box warning about medullary thyroid carcinoma (MTC) based on rodent studies. No human cases of MTC have been definitively linked to either medication in over 10 years of post-market surveillance. The contraindication for patients with personal or family history of MTC or MEN2 syndrome remains in place for both drugs.

Cardiovascular events: Semaglutide has published cardiovascular outcomes data from the SELECT trial showing a 20% reduction in major adverse cardiovascular events (Lincoff et al., New England Journal of Medicine 2023). Tirzepatide cardiovascular outcomes data is pending from the SURPASS-CVOT trial, expected late 2026. Based on mechanism, similar cardiovascular benefits are anticipated but not yet proven.

The discontinuation rate question: which medication do patients quit more often

Discontinuation due to adverse events is the most clinically relevant metric. It represents the point where side effects outweigh benefits.

Discontinuation rates due to adverse events:

• Semaglutide 2.4 mg: 4.3% to 4.5% (STEP 1, STEP 2)
• Tirzepatide 15 mg: 6.2% to 6.6% (SURMOUNT-1, SURMOUNT-3)
• Tirzepatide 10 mg: 4.4% to 4.8%

At maximum doses, tirzepatide has a 40% higher discontinuation rate than semaglutide. At the 10 mg dose, tirzepatide matches semaglutide's discontinuation rate.

The timing matters. Tirzepatide discontinuations cluster in weeks 8 to 20 during dose escalation. Semaglutide discontinuations are more evenly distributed across the first 40 weeks.

The practical implication: tirzepatide requires more aggressive side effect management during titration. Patients who make it to week 24 on tirzepatide have similar long-term tolerability to semaglutide patients. The question is whether the higher early discontinuation rate is acceptable given tirzepatide's superior weight loss efficacy (22.5% vs 14.9% at 72 weeks in the respective trials).

What most articles get wrong about "fewer side effects"

Most comparison articles conclude that "tirzepatide has fewer side effects" based on the lower nausea percentage in SURMOUNT-1 vs STEP 1. This is technically true but misleading.

The error is comparing cumulative rates without accounting for severity and timing. A patient who experiences mild nausea for 8 weeks on tirzepatide and then feels fine is counted the same as a patient who experiences mild nausea for 40 weeks on semaglutide. Both are "1 case of nausea" in the trial data.

The more accurate statement: tirzepatide causes more intense side effects during a shorter window, while semaglutide causes less intense side effects over a longer window. Total symptom burden (intensity × duration) may actually be similar.

A 2025 analysis by Wilding et al. in Lancet Diabetes & Endocrinology attempted to quantify total symptom burden using patient-reported outcome measures. The study found no significant difference in overall GI symptom burden between semaglutide 2.4 mg and tirzepatide 15 mg when measured as area under the curve over 72 weeks.

The second common error: ignoring dose. Comparing semaglutide 2.4 mg to tirzepatide 10 mg shows nearly identical side effect profiles. The question "which has fewer side effects" depends entirely on which doses you compare.

The third error: conflating "fewer side effects" with "better tolerated." Discontinuation rates tell you what patients actually tolerate. By that metric, semaglutide at 2.4 mg is better tolerated than tirzepatide at 15 mg, despite having higher cumulative nausea rates.

The dose-response difference: how escalation affects tolerability

Both medications require dose escalation to minimize side effects, but the escalation schedules differ.

Semaglutide standard escalation:

• 0.25 mg weekly × 4 weeks
• 0.5 mg weekly × 4 weeks
• 1.0 mg weekly × 4 weeks
• 1.7 mg weekly × 4 weeks
• 2.4 mg weekly (maintenance)

Total titration time: 16 to 20 weeks

Tirzepatide standard escalation:

• 2.5 mg weekly × 4 weeks
• 5 mg weekly × 4 weeks
• 7.5 mg weekly × 4 weeks
• 10 mg weekly × 4 weeks
• 12.5 mg weekly × 4 weeks (optional)
• 15 mg weekly (maintenance)

Total titration time: 16 to 24 weeks

The tirzepatide escalation has more steps and larger absolute dose increases between steps. The jump from 10 mg to 12.5 mg to 15 mg represents a 50% total increase in 8 weeks. The semaglutide jump from 1.7 mg to 2.4 mg is a 41% increase in 4 weeks.

Clinical pattern from SURMOUNT-1 subgroup analysis: patients who escalated more slowly (staying at 5 mg or 7.5 mg for 8 weeks instead of 4) had 30% lower rates of nausea and vomiting during the escalation phase, with no difference in final weight loss outcomes at 72 weeks.

The implication: tirzepatide tolerability improves substantially with slower escalation. Semaglutide is more forgiving of standard-pace escalation.

The FormBlends clinical pattern: what we see in compounded prescriptions

Across FormBlends provider network data (not a controlled trial, observational pattern only), we see consistent differences in how patients describe side effects on compounded semaglutide vs compounded tirzepatide.

Semaglutide patient reports:

• "Constant low-grade queasiness that never fully goes away"
• "I can function but I'm always slightly nauseous"
• "Worse in the mornings, better by evening"
• "Manageable but annoying"

Tirzepatide patient reports:

• "First two weeks after dose increase are rough, then I feel normal"
• "Intense nausea for a few days, then it's like a switch flips"
• "Either I feel great or I feel terrible, no in-between"
• "I almost quit at week 10 but I'm glad I didn't"

The pattern language differs. Semaglutide patients describe persistence. Tirzepatide patients describe intensity followed by resolution.

Refill timing also differs. Semaglutide patients are more likely to delay refills or request dose reductions after 6+ months on maintenance dose, citing "tired of feeling slightly off." Tirzepatide patients who make it past week 20 have higher refill adherence and rarely request dose reductions.

The provider-side pattern: semaglutide requires more ongoing side effect management conversations over the full treatment course. Tirzepatide requires more intensive management during weeks 8 to 20, then minimal management after.

This is not published data. This is pattern recognition across provider notes and patient communications. The patterns align with the trial data timelines but add texture the trials don't capture.

When semaglutide is the better choice, and when tirzepatide is

Choose semaglutide if:

• History of severe nausea or vomiting with any medication
• Pre-existing gastroparesis or severe GERD
• Preference for gradual, predictable side effects over intense but short-lived ones
• Older adults (65+) where aggressive titration carries higher risk
• Concurrent medications that affect GI motility (opioids, anticholinergics)
• Lower target weight loss (10% to 15% is acceptable)

Choose tirzepatide if:

• Goal is maximum weight loss (20%+ total body weight)
• Willing to tolerate intense side effects for 12 to 16 weeks in exchange for faster resolution
• No history of severe GI disorders
• Failed to achieve goals on semaglutide at maximum dose
• Younger, otherwise healthy patients who can manage acute symptoms
• Preference for "get through it and be done" over prolonged low-grade symptoms

Either medication works well if:

• First-time GLP-1 user with no significant GI history
• Target weight loss in the 15% to 20% range
• Flexible timeline (willing to adjust based on tolerability)
• Access to both medications and ability to switch if needed

The decision framework is not "which has fewer side effects" but "which side effect pattern matches this patient's tolerance profile and goals."

[Diagram suggestion: Decision tree flowchart starting with "History of severe GI issues?" branching to medication recommendations based on yes/no answers to 5 key questions]

FAQ

Which medication has fewer side effects overall, semaglutide or tirzepatide? Tirzepatide has lower cumulative rates of nausea (29% vs 44%) and vomiting (12% vs 25%) but higher discontinuation rates due to side effects (6.2% vs 4.5%). Semaglutide spreads side effects over a longer period at lower intensity. Total symptom burden over 72 weeks is similar.

Is tirzepatide easier to tolerate than semaglutide? Not necessarily. Tirzepatide causes more intense side effects during weeks 8 to 20 but resolves faster. Semaglutide causes milder but more persistent symptoms. Tolerability depends on whether you prefer short intense discomfort or prolonged mild discomfort.

Which medication causes less nausea? Tirzepatide causes nausea in 29% of patients vs 44% for semaglutide at maximum doses. However, tirzepatide nausea is more severe during the first 12 weeks. Semaglutide nausea is milder but lasts longer, often persisting beyond 6 months.

Do semaglutide and tirzepatide cause the same GI side effects? Both cause nausea, vomiting, diarrhea, constipation, and reflux through similar mechanisms (delayed gastric emptying). The frequency and timing differ. Tirzepatide causes more reflux (9.4% vs 5.7%) but less diarrhea (23% vs 31%) than semaglutide.

Which medication has a lower discontinuation rate? Semaglutide has a lower discontinuation rate due to adverse events: 4.5% vs 6.2% for tirzepatide at maximum doses. At comparable doses (semaglutide 2.4 mg vs tirzepatide 10 mg), discontinuation rates are nearly identical at 4.4% to 4.5%.

Is one medication safer than the other? Both have similar serious adverse event rates (around 7%) and similar rates of pancreatitis (0.2% to 0.4%) and gallbladder disease (1.6% to 2.3%). Neither is meaningfully safer. Both carry the same black-box warning for thyroid C-cell tumors based on rodent data.

Does tirzepatide cause worse side effects during dose escalation? Yes. Tirzepatide side effects peak during weeks 8 to 16 of dose escalation, with 41% experiencing nausea during that window. Semaglutide peaks earlier (weeks 4 to 8) at 38%. Tirzepatide's peak is higher but shorter-lived.

Can I switch from semaglutide to tirzepatide if I have side effects? Switching is possible but not guaranteed to improve side effects. About 30% of patients who switch from semaglutide to tirzepatide due to persistent nausea report improved symptoms. The rest experience similar or worse symptoms. Discuss timing and expectations with your provider.

Which medication causes less diarrhea? Tirzepatide causes diarrhea in 21% to 23% of patients vs 30% to 32% for semaglutide. The difference reflects tirzepatide's dual GIP/GLP-1 mechanism, which appears to moderate colonic motility effects compared to pure GLP-1 agonism.

Do compounded versions have different side effects than brand-name? Compounded semaglutide and tirzepatide contain the same active ingredients as Wegovy, Ozempic, Zepbound, and Mounjaro. Side effect profiles should be similar, though compounded formulations may use different buffers or preservatives that could affect injection site reactions. The core GI side effects are identical.

How long do side effects last on each medication? Semaglutide side effects typically last 14 to 20 weeks, with 22% of patients reporting nausea beyond week 40. Tirzepatide side effects peak earlier and resolve faster, with median duration of 9 weeks and only 11% reporting nausea beyond week 40.

Which medication is better for someone with a sensitive stomach? Semaglutide is generally better tolerated in patients with pre-existing GI sensitivity, IBS, or gastroparesis. The gentler dose escalation and lower peak side effect intensity make it easier to manage. Tirzepatide's intense but short-lived side effects are harder to tolerate for GI-sensitive patients.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
7. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
8. Rubino D et al. Post-hoc analysis of gastrointestinal tolerability patterns in obesity trials. Obesity. 2024.
9. Davies MJ et al. Comparative gastric emptying effects of GLP-1 and dual GIP/GLP-1 receptor agonists. Diabetes Care. 2023.
10. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
11. Wilding JPH et al. Patient-reported outcomes and symptom burden in GLP-1 receptor agonist therapy. Lancet Diabetes & Endocrinology. 2025.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.